31 Biotechnology, Immunology & Pharmaceuticals
High-throughput Service for Mutational Activity Maps of Therapeutic Proteins Introduced
ProImmune have announced the introduction of MutaMap™, a new high-throughput assay service for understanding the impact of point mutations on protein therapeutic activity, including monoclonal antibodies. MutaMap provides a high- throughput service, with high-quality output data, to help decide which individual point mutations to pursue and enable better protein engineering decisions to be made, prior to committing a drug candidate to a clinical program.
MutaMap is an in vitro assay system that explores the effect of deliberate point mutations on protein activity by substituting each of the 19 possible amino acid alternatives in each position in a protein sequence, one by one. Each position of a protein of interest is altered by site-directed mutagenesis, expressed and changes in affinity or activity measured using cell- free in vitro translation of proteins and solution titration assays. These methods avoid the use of surrogate measurements for affinity or activity and have been optimised for high-throughput processing of samples without compromising on readout accuracy. The technology is particularly suited for investigating a range of the ligand-binding interactions, from high-affinity monoclonal antibodies down to the high-femtomolar range where other approaches, such as surface plasmon resonance (SPR), struggle to deliver results in high throughput.
MutaMap can deliver a high-throughput mutagenesis project for exploring 500-2000 mutations in approximately 8-12 weeks and deliver a heat map for the protein sequence of interest, showing which point mutations lead to an increase, decrease, or no change in affinity (or other activity), or non-function of the protein of interest when interacting with one, or more, of its binding partners. This effectively reveals which mutations are likely permissible or favourable for protein engineering and provides a novel tool for making informed decisions across a range of key developability objectives. These can include cherry picking mutations to improve activity, de-immunisation, altering cross-species reactivity, improved humanisation or provision of other engineered features, stability and manufacturability, prolonging half-life and developing unique new composition of matter IP.
MutaMap is the first service ProImmune is offering in the area of protein engineering. The technology is complementary to the company’s existing technologies for assessing the antigenicity of therapeutic proteins and can be readily combined with ProImmune’s leading ProMap® and ProScern® T cell assays, ProPresent® Antigen Presentation Assays and ProImmune REVEAL® MHC-peptide binding assays.
44732pr@reply-direct.com 8649ad@reply-direct.com
New Offering of Human Liver Microsomes for Drug Metabolism Studies Announced
Lonza Walkersville has announced its new offering of Silensomes™ Human Liver Microsomes (HLM) products, pooled human liver microsomes for in vitro cytochrome P450 (CYP) phenotyping. CYP phenotyping is a regulatory requirement for new drug candidates to understand their metabolism and to predict drug-drug interactions.
Lonza Walkersville’s new Silensomes™ HLM products provide researchers a fully characterised pre-made solution for CYP phenotyping, resulting in more consistent and reliable results.
Lonza’s Silensomes™ HLM products include seven
cryopreserved human liver microsomes pools that are each pre-treated with a mechanistic-based inhibitor targeting a single CYP enzyme. This chemical inactivation is mechanism-based and irreversible, giving researchers confidence that their results are accurate and reliable. Each of the seven CYP Silensomes™ HLM are packaged as Silensomes™ CYP Phenotyping Kits to include a production-matched control microsome that was treated the same way without the inhibitor. A panel consisting of all seven Silensomes™ HLM with a single matched control is also available.
This new product offering from Lonza is a result of the company’s recent agreement with Biopredic International and strengthens Lonza’s position as a leading supplier of ADME-Tox products for scientists working in drug development. The addition of Silensomes™ HLM products expands Lonza’s extensive ADME-Tox portfolio, which includes fresh and cryopreserved human and animal primary hepatocytes, specialised media and cell culture systems.
“With regulatory authorities specifying CYP phenotyping as part of the drug development process, we wanted to support scientists working in this area by offering more-reliable and easier-to-use models,” said Maureen Bunger, Product Manager for ADME-Tox Solutions at Lonza. “Our Silensomes™ HLM products are supplied in a ready-to-use format and provide a single in vitro solution for CYP phenotyping, helping to simplify drug metabolism studies for researchers.”
44729pr@reply-direct.com The Spotlight could be on you!
Contact Gwyneth Astles on +44 (0)1727 855574 or email:
gwyneth@intlabmate.com
new
Clipmax - Cell culture directly on slide
Premium class for tissue culture
Life Science products in top-quality since 1966. Professional consulting. Worldwide support.
Innovation - made in Switzerland.
www.tpp.ch
SWISS QUALITY
New Herpes Virus Monoclonal Antibodies
Herpes simplex viruses (HSV) types 1 & 2 cause both oral and genital infections. The resulting skin blisters are painful and can last two or more weeks before healing. These viruses lay dormant in nerve cells and can reactivate causing a return of blisters. Infection lasts a lifetime and currently there is no cure.
The viruses produce a number of diagnostically significant antigens including glycoproteins D and G.
ViroStat has just released new Monoclonal Antibodies to HSV glycoproteins D and G. These are useful tools for developing rapid assays to detect these viral antigens.
Go to
www.virostat-inc.com to download the data sheets of these new antibodies.
44731pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
